<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607643</url>
  </required_header>
  <id_info>
    <org_study_id>Olympian</org_study_id>
    <nct_id>NCT03607643</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies</brief_title>
  <official_title>Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leaf Vertical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leaf Vertical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the
      Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma
      Multiforme, Multiple Myeloma, and GI Malignancies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have shown a potential anti-tumor role for cannabinoids by modulating cell
      signaling pathways, inhibiting angiogenesis, inducing apoptosis, and overcoming chemotherapy
      resistance. In phase I trials, cannabinoids have been shown to enhance the uptake of
      chemotherapy into malignant cells without affecting normal cells. The investigators seeks to
      demonstrate that the combination of chemotherapy with BRCX014 will have a greater anti-tumor
      and anti-proliferative activity when compared to standard of care alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Study length for randomized patients in the treatment group(s) will be 180 days. For those subjects randomized into the control group(s), after 90 days of the control group study treatment, will be given the choice to rollover into the treatment group. Crossover is also permitted if there is progression of disease before 90 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, care provider, investigator, and outcomes assessor will be blinded to standard of care (SOC) alone vs treatment arm</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>The primary objective of this study is to evaluate the overall response rates of cancer patients as assessed by standard criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) in patients using lab results and radiographic data.</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>A secondary objective of this study is to measure TTP using lab results and radiographic data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in patients using lab results and radiographic data.</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>A secondary objective of this study is to measure PFS using lab results and radiographic data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life assessment in patients using patient-reported outcomes (PRO) data.</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>A secondary objective of this study is to collect patient-reported outcomes (PRO) data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>A secondary objective of this study is to collect clinician-reported outcomes (ClinRO) data.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cancer of Pancreas</condition>
  <condition>Cancer of Liver</condition>
  <condition>Cancer of Rectum</condition>
  <condition>Cancer of Colon</condition>
  <condition>Cancer, Gall Bladder</condition>
  <condition>Myeloma Multiple</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Colon: Chemo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal: Chemo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple myeloma: Chemo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 &amp; 11 schedule to be repeated every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple myeloma: Chemo + BRCX014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 &amp; 11 schedule to be repeated every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic: Chemo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic: Chemo + BRCX014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBM: Chemo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBM: Chemo + BRCX014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day
Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal</description>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_label>GBM: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Multiple myeloma: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Pancreatic: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <other_name>BRCX014</other_name>
    <other_name>bioRenovate CX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 &amp; 11 schedule to be repeated every 21 days.</description>
    <arm_group_label>Multiple myeloma: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Multiple myeloma: Chemo + Placebo</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Colon: Chemo + Placebo</arm_group_label>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Rectal: Chemo + Placebo</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Colon: Chemo + Placebo</arm_group_label>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Rectal: Chemo + Placebo</arm_group_label>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Colon: Chemo + Placebo</arm_group_label>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Rectal: Chemo + Placebo</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Colon: Chemo + Placebo</arm_group_label>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Rectal: Chemo + Placebo</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.</description>
    <arm_group_label>Colon: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Colon: Chemo + Placebo</arm_group_label>
    <arm_group_label>Rectal: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Rectal: Chemo + Placebo</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.</description>
    <arm_group_label>Pancreatic: Chemo + BRCX014</arm_group_label>
    <arm_group_label>Pancreatic: Chemo + Placebo</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).</description>
    <arm_group_label>GBM: Chemo + BRCX014</arm_group_label>
    <arm_group_label>GBM: Chemo + Placebo</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent

          2. Male and Females age 18 to 80 years old at the time of screening

          3. Confirmed tissue diagnosis of Multiple myeloma, GI malignancy by a licensed
             pathologist

          4. A performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale.

          5. Females of childbearing potential willing to utilize two approved forms of
             contraceptives (e.g., birth control, abstinence, spermicidal lube, intrauterine device
             [IUD])

          6. Male study subjects must be willing to use two approved forms of contraceptives (e.g.,
             physical barrier-condoms, abstinence, spermicidal lube)

        Exclusion Criteria:

          1. Subject is pregnant or plans to become pregnant or actively lactating/nursing

          2. Hypersensitivity to any ingredient in the study product

          3. Initial laboratory values as determined by the principal investigator to be clinically
             significant

          4. A substance abuse history within the last five years

          5. Any diseases or conditions that may interfere with the conduct of the study or
             interpretation of the study results

          6. .Close affiliation with the investigational site (e.g., a close relative of the
             investigator), dependent person (employee or student of investigational site, or
             sponsor's staff)

          7. Currently enrolled in another investigational clinical study

          8. A known history of severe depression or psychiatric disorders or active suicidal
             ideation

          9. Inability or unwillingness to cooperate with the study procedures for any reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah F Katta, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leaf Vertical Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Arlen, PhD</last_name>
    <phone>407-443-0656</phone>
    <email>parlen@leafvertical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Fisher</last_name>
    <phone>407-797-2332</phone>
    <email>ceo@leafvertical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southwest Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Katta, DO</last_name>
      <phone>407-426-8660</phone>
      <email>sarahfk1978@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Philip Arlen, PhD</last_name>
      <phone>407-443-0656</phone>
      <email>parlen@leafvertical.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>July 22, 2018</last_update_submitted>
  <last_update_submitted_qc>July 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

